Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
Exploring possible treatment options after virological failure with raltegravir

In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

Published
21 January 2015
From
CATIE
New anti HIV drug dolutegravir is effective at low doses

The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.

Published
21 January 2015
From
MMD Newswire
Drug Resistance, While Rare, Can Occur After Contracting HIV on PrEP

For the first time, a study has shown that, although rare, resistance to Truvada can develop if someone contracts HIV while taking the drug as PrEP.

Published
16 January 2015
From
AIDSMeds
Drug-resistant infections could lead to 10 million extra deaths a year – report

The stark figures, published on Thursday, and believed to be the first to quantify the potential impact of antimicrobial resistance (AMR) – drug-resistant infections or superbugs – will be used to make the case to global leaders that urgent action is needed. To put the figures in context there are currently 8.2 million deaths a year from cancer and annual global GDP stands at $70tn to $75tn, with the UK figure around $3tn.

Published
11 December 2014
From
The Guardian
What are the barriers that could stop HIV treatment becoming HIV prevention?

One of the key strategies involved in trying to bring an end to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral therapy

Published
12 November 2014
By
Gus Cairns
Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy

Darunavir/ritonavir monotherapy results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs), but may

Published
07 November 2014
By
Keith Alcorn
Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex

A phase one dose-finding and safety study in humans of TMC278 LA, a long-acting, injectable formation of the antiretroviral (ARV) drug rilpivirine, found that a single

Published
01 November 2014
By
Gus Cairns
Emerging epidemic of transmitted HIV drug resistance in low- and middle-income countries, with highest burden seen in MSM

Prevalence of transmitted drug-resistant HIV has doubled in low- and middle-income countries in recent years, results of a meta-analysis published in AIDS show. Between 2004-08 and 2009-13,

Published
28 October 2014
By
Michael Carter
Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs

An analysis of people who experienced treatment failure on their first-line HIV therapy with a viral load of over 400 copies/ml and who had taken either

Published
09 September 2014
By
Gus Cairns
Dolutegravir demonstrates good efficacy despite resistance

Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who had virus with resistance to

Published
24 July 2014
By
Liz Highleyman
← First12345...30Next →

Filter by country